Sanofi's Sarclisa has played second fiddle to Johnson & Johnson's Darzalex in the treatment of multiple myeloma (MM), but the company hopes a new delivery option could give it more of a leading role.

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on procedural ...

Multiple Scripts: Add as many custom JavaScript snippets as you want. Organized UI: Each script is managed in its own collapsible section, keeping your configuration clean and easy to navigate. Enable ...